# US 2019/0167693 A1 · METHOD OF TREATING PATIENTS COADMINISTERED A FACTOR Xa INHIBITOR AND VERAPAMIL

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167693 A1
- Document ID: US20190167693A1
- Status: Published application
- Kind: A1
- Application number: 16/225,910
- Filed: 2018-12-19
- Published: 2019-06-06
- Earliest claimed: 2016-02-23
- Assignees: Morgandane Scientific, LLC
- Applicants: Morgandane Scientific, LLC
- Inventors: Sundar SRINIVASAN; Maulik PATEL; Christina CHOW
- Web page: https://patentgrep.com/patent/US20190167693A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/277: having a ring, e.g. verapamil
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

## Claims

### Claim 1

A method of reducing the risk of cardiovascular death, myocardial infarction, and stroke in a patient in need of treatment with rivaroxaban and verapamil, comprising:
(a) administering about 100 to about 480 mg verapamil daily to the patient; and
(b) administering a daily dose of 2.5 mg to 4 mg of rivaroxaban to the patient;
wherein the patient has a creatinine clearance (CLCr) of >50 mL/min to 79 mL/min.

### Claim 2 (depends on 1)

The method of claim 1, wherein a daily dose of 2.5 mg of rivaroxaban is administered.

### Claim 3 (depends on 1)

The method of claim 1, wherein a daily dose of 3-4 mg of rivaroxaban is administered.

### Claim 4 (depends on 1)

The method of claim 1, wherein a daily dose of 4 mg of rivaroxaban is administered.

### Claim 5 (depends on 2)

The method of claim 2, wherein the rivaroxaban is administered twice daily.

### Claim 6 (depends on 3)

The method of claim 3, wherein the rivaroxaban is administered twice daily.

### Claim 7 (depends on 4)

The method of claim 4, wherein the rivaroxaban is administered twice daily.

### Claim 8 (depends on 2)

The method of claim 2, further comprising administering aspirin to the patient.

### Claim 9 (depends on 3)

The method of claim 3, further comprising administering aspirin to the patient.

### Claim 10 (depends on 4)

The method of claim 4, further comprising administering aspirin to the patient.